Showing 1–25 of 104 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Zh. T. Zhandauletova, Е. И. Никишова, А. O. Мaryandyshev, K. S. Serikbaeva, M. M. Adenov, et al.
…he objective : to assess the safety and compliance with new regimens for preventive treatment of drug susceptible and drug resistant tuberculosis. Subjects and Methods . The study was carried out in Almaty, the Republic of Kazakhstan; 182 patients from the groups facing the high …
Susan Dorman, MD, Payam Nahid, MD, MPH, Susan Swindells, MBBS, Richard Chaisson, MD, Ekaterina V Kurbatova, MD, PhD, MPH
…of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a standard six-month regimen for treatment of pulmonary tuberculosis (TB). All three regimens are administered daily, seven days each week, with direct observation o…
Lindsay McKenna, Jennifer Furin
… needed on the safety and efficacy of pretomanid-containing regimens, and such data can be found in the paper published in The Lancet Respiratory Medicine by Conor Tweed and colleagues.6Tweed CD Dawson R Burger DA et al.Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide duri…
First Affiliated Hospital of Zhejiang University
…o determine whether the sitafloxacin-containing three-month regimens are as effective as the standard six-month regimen and the four-month rifapentine and moxifloxacin regimen (substitution of rifapentine for rifampin and moxifloxacin for ethambutol) for treatment of pulmonary tu…
Shanghai Pulmonary Hospital, Shanghai, China
…ity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible tuberculosis. This is a prospective, randomized, controlled, multicenter study planned to enroll 45 rifampicin-susceptible…
Beijing Chest Hospital
…dard of care in China has historically involved 18-20 month regimens, the World Health Organization (WHO) has recently endorsed shorter, all-oral regimens. The BLMZ regimen, composed of Bedaquiline (B), Linezolid (L), Moxifloxacin (M), and Pyrazinamide (Z), demonstrated high effi…
В. П. Гусева, Irina Vasilyeva, V. V. Testov
…dities. Therefore, developing alternative shortened therapy regimens with a favourable safety profile and proven efficacy remains an urgent task. Objective To compare the effectiveness of treatment of pulmonary TB with preserved susceptibility of M. tuberculosis to isoniazid, rif…
Banurekha Velayutham, M S Jawahar, Chandrasekaran Padmapriyadarsini
…ence to our paper entitled ‘4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India – a randomised clinical trial’ in the letter ‘False equivalence of four month and six-month ATT regimen: A case of comparin…
Stephanie Palacios, Glenford Refre, Patricio Palmes, Ma. Cecilia Momville
…abases, comparing the 4-month and 6-month anti-TB treatment regimens. RCTs that were published in the English language from 2017-2022 that used drug susceptible TB adult patients were included in the final meta-analysis. We compared the efficacy and safety of the two regimens usi…
Shenjie Tang, MD
…udy is to evaluate the safety and efficacy of two shortened regimens for newly diagnosed smear positive drug susceptible pulmonary tuberculosis in comparison to World Health Organization recommended standard 6-month regimen. 1. Design: The study is a multi-center, randomized,con…
Susan Shin-Jung Lee, M.D., Ph.D.
The development of efficacious, safe, and shorter treatment regimens could significantly improve TB management and treatment success rates. This prospective, 3-year, single arm study is to evaluate the efficacy and safety of a short-course, 4-month regimen including isoniazid(H),…
Susan Shin-Jung Lee, MD, PhD
…The development of efficacious, safe, and shorter treatment regimens could significantly improve treatment completion rate and reduce transmission of TB. The current treatment guidelines for drug-susceptible TB from the World Health Organization (WHO), American Thoracic Society (…
Alina Malic, Adriana Niguleanu, Tatyana Osipov
Treatment of tuberculosis (TB) includes various therapeutic regimens with a combination of at least four drugs. Adherence to the treatment regimen is crucial for efficacy outcomes based on the achievement of appropriate drug levels. Drug-resistant () strains are mainly favored by…
Nisha Wanichwecharungruang, Weerinth Puyati, Thanyanuch Sanchat
Abstract Introduction: The 4-month rifapentine-moxifloxacin (HPMZ) regimen has recently been shown to be as effective as the standard 6-month rifampicin-based regimen for drug-susceptible pulmonary tuberculosis. Clinical trials reported serious adverse drug reactions (ADRs) in on…
Gustavo Velásquez, MD, MPH, Patrick Phillips, PhD, Susan Dorman, MD
…domized to SOC or one of five durations of the experimental regimens while those classified into the higher-risk group will be randomized to receive either SOC or a single fixed duration of the experimental regimen. The lower and higher-risk groups will have the following arms: …
Nelly Solomonia, K Vacharadze
…the all anti-TB drugs and to build an appropriate treatment regimens based on complete individual DST profile in timely manner. Initial TB treatment regimen prescribed based on gDST results not in all cases may be compliant with complete DST profile, which may be detected based o…
Jia-Yih Feng, Chin‐Chung Shu, Shu Min Lin, Ya-Wei Weng, Jui-Kuang Chen, et al.
… epidemic by 2030. Efficacious, safe, and shorter treatment regimens may significantly improve treatment success rates, and reduce TB incidence and mortality. The aim of this study is to evaluate the efficacy and safety of a short-course, 4-month regimen (2HZPM/2HPM) in the Asian…
Shenzhen Third People's Hospital
…). Despite the availability of effective standard treatment regimens, the current 6-month therapy duration poses challenges in terms of patient adherence, resource allocation, and overall treatment success. In recent years, ultrashort-course regimens for DS-TB have been proposed…
Nicole Salazar-Austin, MD, ScM
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs. Shorter treatment may be easier for children to tolerate and finish as well as e…
John Metcalfe, MD, PhD, MPH
The purpose of this study was to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with a CFZ loading dose with the 6-month standard of care (SOC) regimen for drug-susceptible (DS) tuberculosis (TB). This study compared a 3-month rifapentine (RPT)/clofazim…
Chabala, Chishala
… low-resource settings, modifications typically involve ART regimens due to constrained drug options. This thesis presents four pharmacokinetics and one clinical study evaluating strategies for HIV/TB co-treatment in children and adolescents receiving rifampicin-based TB therapy,…
Shanghai Public Health Clinical Center
This study adopts a multicenter, open-label, randomized controlled design, conducted across key designated AIDS diagnosis and treatment hospitals nationwide. It aims to compare the efficacy and safety of the 2HPMZ/2HPM regimen versus the 2HRZE/4HR regimen in treating HIV-associat…
Radojka Savic, PharmD, PhD, Kelly Dooley, MD, PhD, Gustavo Velásquez, MD, MPH
…m protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as deter…
Oxana Rucsineanu, P. Agbassi, Rosa María Blanca Herrera, Marcus Low, Lindsay McKenna, et al.
… should also be considered when developing new TB treatment regimens, including drug toxicity, time spent in monitoring and overall quality of life while on therapy. We examine the specific use of linezolid in treatment-shortening trials for drug-susceptible TB and propose additi…
Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial will assess the safety and efficacy of OPC-167832 combined with delamanid and bedaquiline in participants with drug-susceptible tuberculosis (DS-TB) administered for 17 weeks compared to rifampin, isoniazid, ethambutol, pyrazinamide (RHEZ) administered for 26 weeks. E…